These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations.
    Author: Kim RJ, Malattia C, Allen M, Moshang T, Maghnie M.
    Journal: Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():115-23. PubMed ID: 16456490.
    Abstract:
    The management of central diabetes insipidus has been greatly simplified by the introduction of desmopressin (DDAVP). Its ease of administration, safety and tolerability make DDAVP the first line agent for outpatient treatment of central diabetes insipidus. The major complication of DDAVP therapy is water intoxication and hyponatremia. The risk of hyponatremia can be reduced by careful dose titration when initiating therapy and by close monitoring of serum osmolality when DDAVP is used with other medications affecting water balance. Herein we review the adverse effects of DDAVP and its predecessor, vasopressin, as well as discuss important clinical considerations when using these agents to treat central diabetes insipidus.
    [Abstract] [Full Text] [Related] [New Search]